Manchester Capital Management LLC
Position in DNLI — Denali Therapeutics Inc.
CIK 1393389
MANCHESTER, VT
Position in DNLI
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$925
+$234 QoQ
Shares Held
36
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#268
of 290 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Manchester Capital Management LLC holds $805,024 across 28 Biotechnology names. DNLI ranks #21 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REPL |
Replimune Group, Inc.
|
25,675 | $284,222 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
391 | $194,221 | |
| 3 | INSM |
INSMED Inc
|
1,033 | $110,138 | |
| 4 | RPRX |
Royalty Pharma plc
|
694 | $38,912 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
47 | $29,306 | |
| 6 | ABVX |
Abivax S.A.
|
200 | $26,652 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
83 | $24,985 | |
| 8 | MRNA |
Moderna, Inc.
|
321 | $22,479 |
All Filings in DNLI
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $925 | 36 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $691 | 36 | Shares | Sole | 2026-05-11 | |
| 2025-12-31 | $594 | 36 | Shares | Sole | 2026-02-11 | |
| No filing history on record for this holder in this stock. | ||||||